ID   HCC78 ROS1 p.G2032R
AC   CVCL_E6J3
RX   DOI=10.63028/10067/2105480151162165141;
RX   PubMed=38433235;
CC   Population: Caucasian.
CC   Characteristics: The ROS1 mutation introduced is most prevalent among patients presenting relapsed disease. Shows significant resistance to ceritinib, crizotinib, entrectinib and lorlatinib (PubMed=38433235).
CC   Sequence variation: Gene fusion; HGNC; HGNC:10261; ROS1 + HGNC; HGNC:11020; SLC34A2; Name(s)=SLC34A2-ROS1 (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Arg58Ter (c.172C>T) (p.Pro72Leu, c.215C>T); ClinVar=VCV000376310; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:10261; ROS1; Simple_edited; p.Gly2032Arg (c.6094G>A) (p.Gly2026Arg, c.6076G>A); ClinVar=VCV000376139; Zygosity=Heterozygous; Note=By CRISPR/Cas9 (PubMed=38433235).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ser241Phe (c.722C>T); ClinVar=VCV000012359; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2061 ! HCC78
SX   Male
AG   65Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   DOI=10.63028/10067/2105480151162165141;
RA   Terrones M.;
RT   "Profiling targeted therapy responses in ROS1+ non-small cell lung
RT   cancer using genomically engineered patient-derived cell lines.";
RL   Thesis PhD (2024); University of Antwerp; Antwerp; Belgium.
//
RX   PubMed=38433235; DOI=10.1186/s12967-024-04988-0; PMCID=PMC10910754;
RA   Terrones M., Deben C., Rodrigues-Fortes F., Schepers A.,
RA   Op de Beeck K., Van Camp G., Vandeweyer G.;
RT   "CRISPR/Cas9-edited ROS1 + non-small cell lung cancer cell lines
RT   highlight differential drug sensitivity in 2D vs 3D cultures while
RT   reflecting established resistance profiles.";
RL   J. Transl. Med. 22:234.1-234.16(2024).
//